AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MGNX · NASDAQ · Biotechnology

MacroGenics

Develops engineered antibody therapies for cancer through internal programs and collaborations.

$4.10

After-hours close−0.04 (−0.97%)

At close$4.14(+1.47%)

Something off on this page? Send us feedback.

Profile

MacroGenics, Inc.MGNXHealth Care

Develops clinical-stage cancer therapies using engineered antibodies, bispecific DART molecules, and antibody-drug conjugates. The business combines internal programs with collaborations, royalties, and selected asset transactions.

Builds clinical-stage oncology programs around Fc-engineered antibodies, bispecific DART molecules, and antibody-drug conjugates. Current internal programs include MGC026, MGC028, and lorigerlimab, alongside collaborations spanning commercial, clinical, and preclinical work.

Operations are rooted in Rockville, Maryland and concentrate on research and development following the sale of GMP manufacturing operations and the CDMO business. Global MARGENZA rights were sold to TerSera, while partnership economics include ZYNYZ royalties and collaborations with Incyte, Sanofi, and Gilead.

Progress depends on clinical data, regulatory actions, collaboration milestones and royalties, and external manufacturing and supply arrangements following the Bora transaction.

Company facts

CEOEric Risser

ListedOct 16, 2013

ExchangeNASDAQ

HeadquartersRockville, MD

CountryUnited States

Employees293

CIK0001125345

ISINUS5560991094

Key statistics

Market cap$262.5M

EPS (ttm)−$0.2200

P/E (ttm)−18.77

ROE-31.3%

P/B6.13

P/S1.57

Dividend yield—

Beta0.99vs XLV 0.59

Year to date +157% · Average volume (30d) 592.9K

Analysts

Price target, next 12 months$6.00+45.3%Median of 22 analysts · vs the Aug 28 close

ConsensusBuy12 of 22 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $4.13

High$6.00+45.3%

Median$6.00+45.3%

Low$6.00+45.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Apr 20, 2026	Barclays	Reiterate		Overweight	$3	$6
Apr 10, 2026	B. Riley Securities	Upgrade	Neutral	Buy
Nov 7, 2024	JMP Securities	Downgrade	Market Outperform	Market Perform

Earnings

EPS

Estimate−$0.29

ReportedDue Nov 11, 2026

Revenue

Estimate$40.6M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 13, 2026Q2 FY26	−$0.08	$0.31	+498.2%	$59.1M	$32.8M	−44.5%	+3.43%
May 14, 2026Q1 FY26	−$0.57	−$0.58	−1.8%	$15.2M	$20.8M	+36.3%	+2.16%
Mar 9, 2026Q4 FY25	−$0.42	−$0.22	+47.6%	$34.6M	$41.2M	+19.2%	+45.34%
Nov 12, 2025Q3 FY25	−$0.48	$0.27	+156.3%	$27.8M	$72.8M	+161.9%	+8.84%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$13.2M	$22.2M	$72.8M	$41.2M	$20.8M	$32.8M
Gross profit	$6.0M	$11.4M	$59.5M	$29.4M	$9.6M	−$13.9M
Operating income	−$42.6M	−$36.8M	$18.6M	−$12.1M	−$33.4M	−$13.9M
Net income	−$41.0M	−$36.3M	$16.8M	−$14.2M	−$36.8M	$19.5M
Diluted EPS	−$0.65	−$0.57	$0.27	−$0.22	−$0.58	$0.31
Gross margin	45.6%	51.4%	81.6%	71.3%	46.0%	-42.2%
Operating margin	-323.1%	-165.3%	25.6%	-29.3%	-161.0%	-42.2%

Fiscal years (4-quarter sums)FY21 $77.4M · FY22 $151.5M · FY23 $58.7M · FY24 $148.3M · FY25 $149.5M

Revenue by product · Q2 FY26

Royalty$255.0M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $173.3M · Total debt $35.1M · Total assets $345.4M · Shareholders' equity $42.9M

Dividends

No dividends on record.

Ownership

Institutions 67.92%43.17M sharesInsiders 3.27%2.08M sharesOther 28.81%18.31M shares

Shares outstanding 63.56M · Float 55.88M · 87.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Armistice Capital, LLC	6.01M	9.46%	13G	May 15, 2026
BlackRock, Inc.	4.50M	7.10%	13G	Jul 29, 2026
Millennium Management LLC	3.44M	5.40%	13G	Jun 5, 2026
Bank of America Corp /DE/	3.26M	5.10%	13G	May 14, 2026
Patrick J. Heron	3.18M	5.10%	13G	Nov 20, 2024

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 19, 2026	Jeffrey Stuart Peters	officer: Senior VP, GC, and Secretary	−31,105	$4.15